Clinical Trial Update: Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing extended-release rabeprazole 50 mg to esomeprazole 40 mg for healing and symptomatic relief in mild-to-moderate erosive gastroesophageal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• AcipHex ER (rabeprazole extended-release) (rabeprazole)
• Nexium (esomeprazole)

Snippet

Sponsor: Eisai Inc. | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED | Results posted: 2015-06-23